Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Plain-language summary

Objective To examine the short-term cognitive and behavioral effects of L-deprenyl in persons with mild dementia of the Alzheimer type (DAT) over a 2-month period. Design A 15-month randomized, double-blind, placebo-controlled trial using a parallel-group design. This report deals with the first 2 months of the trial. Participants 39 subjects with mild DAT (CDR 1) selected using NINCDS-ADRDA criteria. Measures A battery of neuropsychological tests and clinical rating scales. Results The placebo and L-deprenyl subjects were similar at baseline on the clinical and neuropsychological tests. There was no evidence of a L-deprenyl effect on any clinical or neuropsychological measures after 2 months. Conclusion L-deprenyl did not have a measurable impact on behavior or cognitive function over a 2-month period in this group of subjects with mild DAT.

What this study adds

Evidence grade: High

This is a trial of 39 participants. In this 2-month report from a trial of 39 people with mild dementia of the Alzheimer type, L-deprenyl had no measurable effect on behavior or cognitive function compared with placebo. The authors concluded L-deprenyl did not have a measurable impact over this period.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Burke, W. J., Ranno, A. E., Roccaforte, W. H., Wengel, S. P., Bayer, B. L., & Willcockson, N. K. (1993). L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results. Journal of the American Geriatrics Society. https://doi.org/10.1111/j.1532-5415.1993.tb06942.x

Vancouver

Burke WJ, Ranno AE, Roccaforte WH, Wengel SP, Bayer BL, Willcockson NK. L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results. Journal of the American Geriatrics Society. 1993. doi:10.1111/j.1532-5415.1993.tb06942.x. PMID: 8463521.

BibTeX

@article{burke1993-8463521,
  author  = {Burke, W. J. and Ranno, A. E. and Roccaforte, W. H. and Wengel, S. P. and Bayer, B. L. and Willcockson, N. K.},
  title   = {{L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results}},
  journal = {Journal of the American Geriatrics Society},
  year    = {1993},
  doi     = {10.1111/j.1532-5415.1993.tb06942.x},
  pmid    = {8463521},
  url     = {https://doi.org/10.1111/j.1532-5415.1993.tb06942.x}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In this 2-month report from a trial of 39 people with mild dementia of the Alzheimer type, L-deprenyl had no measurable effect on behavior or cognitive function compared with placebo. The authors concluded L-deprenyl did not have a measurable impact over this period.

Study details

How this study scored 53/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 3 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 51 of the 96 points it could be judged on, which is 53 of 100. Total 53 of 100.51 of the 96 points we could judge = 53 of 100

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 51 of the 96 points we could judge it on, which is 53 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of the American Geriatrics Society)
Journal's citation record 3 / 4 Journal of the American Geriatrics Society: journal h-index 344 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1993 — older than 20 years, still counted
Sample size 1 / 4 39 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 3 / 7 Cited 18 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.5 citations a year over 35 year(s) since 1993
Impact for its field and year 2 / 6 Cited 1.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Nancy K. Willcockson holds only 9 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 University of Nebraska Medical Center: institution h-index 666 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 8463521)
Free to read 0 / 2 Behind a paywall — scores zero
Points 51 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 51 of the 96 points we could judge it on is 53 out of 100.
Total 53 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →